menu
    • menu
    [{"orgOrder":0,"company":"BridGene Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"BGC515","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"BridGene Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BridGene Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"BridGene Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"BridGene Biosciences","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"BridGene Biosciences","amount2":0.5,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0.5,"dosageForm":"Undisclosed","sponsorNew":"BridGene Biosciences \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"3","companyTruncated":"BridGene Biosciences \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"BridGene Biosciences","sponsor":"Galapagos","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"BridGene Biosciences","amount2":0.16,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.72999999999999998,"dosageForm":"Undisclosed","sponsorNew":"BridGene Biosciences \/ Galapagos","highestDevelopmentStatusID":"4","companyTruncated":"BridGene Biosciences \/ Galapagos"},{"orgOrder":0,"company":"BridGene Biosciences","sponsor":"Galapagos","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"BridGene Biosciences","amount2":0.72999999999999998,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.72999999999999998,"dosageForm":"Undisclosed","sponsorNew":"BridGene Biosciences \/ Galapagos","highestDevelopmentStatusID":"4","companyTruncated":"BridGene Biosciences \/ Galapagos"},{"orgOrder":0,"company":"BridGene Biosciences","sponsor":"Lapam Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"BridGene Biosciences","amount2":0.040000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.040000000000000001,"dosageForm":"Undisclosed","sponsorNew":"BridGene Biosciences \/ Lapam Capital","highestDevelopmentStatusID":"4","companyTruncated":"BridGene Biosciences \/ Lapam Capital"},{"orgOrder":0,"company":"BridGene Biosciences","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"BridGene Biosciences","amount2":0.81999999999999995,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0.81999999999999995,"dosageForm":"Undisclosed","sponsorNew":"BridGene Biosciences \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"3","companyTruncated":"BridGene Biosciences \/ Takeda Pharmaceutical"}]

    Find Clinical Drug Pipeline Developments & Deals by BridGene Biosciences

    Menu

    BridGene Biosciences

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            BridGene Biosciences

                            U.S.A arrow
                            ISPOR Europe 2025
                            Not Confirmed

                            BridGene Biosciences

                            U.S.A arrow
                            ISPOR Europe 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Study Phase : Discovery Platform

                            Sponsor : Takeda Pharmaceutical

                            Deal Size : $816.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Takeda Pumps $770M into Another BridGene Pact to Hit ‘Undruggable’ Targets

                            Details : The collaboration aims to discover novel small molecule drug candidates by using BridGene chemoproteomics platform, IMTAC, against challenging targets in immunology and neurology.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : $46.0 million

                            February 25, 2025

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Highest Development Status : Discovery Platform

                            Sponsor : Takeda Pharmaceutical

                            Deal Size : $816.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            BridGene Biosciences

                            U.S.A arrow
                            ISPOR Europe 2025
                            Not Confirmed

                            BridGene Biosciences

                            U.S.A arrow
                            ISPOR Europe 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Sponsor : Galapagos

                            Deal Size : $159.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            BridGene Biosciences Expands Collaboration with Galapagos for SMARCA2 PROTAC Development

                            Details : The collaboration aims to advance the molecule into a preclinical candidate for the treatment of cancer with Galapagos holding exclusive rights for further development and commercialization.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            August 01, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Sponsor : Galapagos

                            Deal Size : $159.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            BridGene Biosciences

                            U.S.A arrow
                            ISPOR Europe 2025
                            Not Confirmed

                            BridGene Biosciences

                            U.S.A arrow
                            ISPOR Europe 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BGC515

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of BGC515 Capsules in Subjects With Advanced Solid Tumors

                            Details : BGC515 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Mesothelioma.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            June 11, 2024

                            Lead Product(s) : BGC515

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            BridGene Biosciences

                            U.S.A arrow
                            ISPOR Europe 2025
                            Not Confirmed

                            BridGene Biosciences

                            U.S.A arrow
                            ISPOR Europe 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Sponsor : Galapagos

                            Deal Size : $727.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Galapagos Establishes Collaboration with BridGene for Drug Discovery in Oncology

                            Details : Galapagos and BridGene will collaborate to develop precision oncology medicines by combining Galapagos' small molecule expertise with BridGene's proprietary IMTAC™ chemoproteomics platform.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            January 03, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Sponsor : Galapagos

                            Deal Size : $727.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            BridGene Biosciences

                            U.S.A arrow
                            ISPOR Europe 2025
                            Not Confirmed

                            BridGene Biosciences

                            U.S.A arrow
                            ISPOR Europe 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Study Phase : Discovery Platform

                            Sponsor : Takeda Pharmaceutical

                            Deal Size : $500.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            BridGene Biosciences Achieves Milestone in Takeda Collaboration

                            Details : The collaboration between BridGene and Takeda is based on BridGene's proprietary IMTAC™ chemoproteomics platform, which is used to identify targets and small molecules for Takeda to develop into therapeutic candidates for clinical development.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            March 08, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Highest Development Status : Discovery Platform

                            Sponsor : Takeda Pharmaceutical

                            Deal Size : $500.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            BridGene Biosciences

                            U.S.A arrow
                            ISPOR Europe 2025
                            Not Confirmed

                            BridGene Biosciences

                            U.S.A arrow
                            ISPOR Europe 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Lapam Capital

                            Deal Size : $38.5 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            BridGene Biosciences Announces $38.5 Million Series B Financing to Further Develop Its Next Generation Chemopr...

                            Details : Proceeds from the offering will be used to develop BridGene’s chemoproteomic platform IMTAC™, which enables the screening of small molecules against whole proteome or against a prioritized target in live cells to discover drug candidates and traditio...

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            July 27, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Lapam Capital

                            Deal Size : $38.5 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth